Guidelines for the management of chronic cough in adults
Copyright © 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved..
Patients with chronic cough experience major alteration in their quality of life. Given its numerous etiologies and treatments, this disease is a complex entity. To help clinicians involved in patient management of patients, guidelines have been issued by a group of French experts. They address definitions of chronic cough and initial management of patients with this pathology. We present herein the second-line tests that might be considered in patients whose coughing has persisted, notwithstanding initial management. The experts have also put forward a definition of unexplained or refractory chronic cough (URCC), the objective being to more precisely identify those patients whose cough persists despite optimal management. Lastly, these guidelines indicate the pharmacological and non-pharmacological interventions of use in URCC. Amitriptyline, pregabalin, gabapentin or morphine combined with speech and/or physical therapy are mainstays in treatment strategies. Other treatment options, such as P2X3 antagonists, are being developed and have generated high hopes among physicians and patients alike.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 40(2023), 5 vom: 18. Mai, Seite 432-452 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations de prise en charge de la toux chronique de l’adulte |
|---|
| Beteiligte Personen: |
Guilleminault, L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1806D8D52K |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2023.03.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355846640 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355846640 | ||
| 003 | DE-627 | ||
| 005 | 20231226065219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2023.03.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355846640 | ||
| 035 | |a (NLM)37080877 | ||
| 035 | |a (PII)S0761-8425(23)00106-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Guilleminault, L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidelines for the management of chronic cough in adults |
| 246 | 3 | 3 | |a Recommandations de prise en charge de la toux chronique de l’adulte |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Patients with chronic cough experience major alteration in their quality of life. Given its numerous etiologies and treatments, this disease is a complex entity. To help clinicians involved in patient management of patients, guidelines have been issued by a group of French experts. They address definitions of chronic cough and initial management of patients with this pathology. We present herein the second-line tests that might be considered in patients whose coughing has persisted, notwithstanding initial management. The experts have also put forward a definition of unexplained or refractory chronic cough (URCC), the objective being to more precisely identify those patients whose cough persists despite optimal management. Lastly, these guidelines indicate the pharmacological and non-pharmacological interventions of use in URCC. Amitriptyline, pregabalin, gabapentin or morphine combined with speech and/or physical therapy are mainstays in treatment strategies. Other treatment options, such as P2X3 antagonists, are being developed and have generated high hopes among physicians and patients alike | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic cough | |
| 650 | 4 | |a Excès de sensibilité | |
| 650 | 4 | |a Hypersensitivity | |
| 650 | 4 | |a Neuromodulateurs | |
| 650 | 4 | |a Neuromodulators | |
| 650 | 4 | |a Toux chronique | |
| 650 | 7 | |a Gabapentin |2 NLM | |
| 650 | 7 | |a 6CW7F3G59X |2 NLM | |
| 650 | 7 | |a Amitriptyline |2 NLM | |
| 650 | 7 | |a 1806D8D52K |2 NLM | |
| 700 | 1 | |a Demoulin-Alexikova, S |e verfasserin |4 aut | |
| 700 | 1 | |a de Gabory, L |e verfasserin |4 aut | |
| 700 | 1 | |a Bruley des Varannes, S |e verfasserin |4 aut | |
| 700 | 1 | |a Brouquières, D |e verfasserin |4 aut | |
| 700 | 1 | |a Balaguer, M |e verfasserin |4 aut | |
| 700 | 1 | |a Chapron, A |e verfasserin |4 aut | |
| 700 | 1 | |a Grassin Delyle, S |e verfasserin |4 aut | |
| 700 | 1 | |a Poussel, M |e verfasserin |4 aut | |
| 700 | 1 | |a Guibert, N |e verfasserin |4 aut | |
| 700 | 1 | |a Reychler, G |e verfasserin |4 aut | |
| 700 | 1 | |a Trzepizur, W |e verfasserin |4 aut | |
| 700 | 1 | |a Woisard, V |e verfasserin |4 aut | |
| 700 | 1 | |a Crestani, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 40(2023), 5 vom: 18. Mai, Seite 432-452 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:5 |g day:18 |g month:05 |g pages:432-452 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2023.03.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 5 |b 18 |c 05 |h 432-452 | ||